G A Kanakis1, A Chrisoulidou2, A Bargiota3, Z A Efstathiadou4, L Papanastasiou5, A Theodoropoulou6, S K Tigas7, D A Vassiliadi8, S Tsagarakis9, M Alevizaki10. 1. Department of Endocrinology, Athens Naval & VA Hospital, Athens, Greece. geokan@endo.gr. 2. Department of Endocrinology, Theagenio Cancer Hospital, Thessaloniki, Greece. 3. Department of Endocrinology and Metabolic Diseases, University of Thessaly, Larissa, Greece. 4. Department of Endocrinology, 'Hippokration' General Hospital of Thessaloniki, Thessaloniki, Greece. 5. Department of Endocrinology and Diabetes Center, Athens General Hospital 'G. Gennimatas', Athens, Greece. 6. Division of Endocrinology, Department of Internal Medicine, University Hospital of Patras, Rio, Greece. 7. Department of Endocrinology, University of Ioannina, Ioannina, Greece. 8. Endocrine Unit, 2nd Department of Internal Medicine - Propaedeutic, Research Institute and Diabetes Center, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 9. Department of Endocrinology, Evangelismos Hospital, Athens, Greece. 10. Endocrine Unit, Department of Medical Therapeutics, Medical School, University of Athens, Athens, Greece.
Abstract
OBJECTIVE: Growth hormone (GH) and insulin-like growth factor I (IGF-I) are the principal biomarkers used to assess disease activity in acromegaly, and any discrepancy between them renders interpretation of results inconclusive. Purpose of this study was to assess the frequency of this discrepancy and identify parameters that might affect its occurrence. DESIGN: A systematic review of MEDLINE and Scopus was performed (1987-2013) followed by a meta-analysis to address the frequency of discrepant results between GH and IGF-I levels. Meta-regression and subgroup analyses were performed assessing the effects of the year of publication, the different types of GH testing and GH assays used, as well as the impact of treatment with somatostatin analogues (SSAs) on the occurrence of this discrepancy. RESULTS: The analysis retrieved 39 eligible studies totalling 7071 patients. The pooled discordance rate between GH and IGF-I was 25·7% (95% CI: 22·3-29·4), and the predominant format was that of elevated IGF-I with normal GH levels (15·3%, 95% CI: 12·5-18·7). No significant correlation between the discordance rate and the year of publication was shown; whereas, the use of ultrasensitive GH assays resulted in higher discordance rates (30·7%, 95% CI: 25·9-35·9 vs 19·8%, 95% CI: 14·1-27·2, P = 0·04) as did treatment with SSAs (32·5%, 95% CI: 27·8-37·4) vs (21·6%, 95% CI: 17·8-25·6, P = 0·001). CONCLUSIONS: Discrepancy between GH and IGF-I results is encountered in a quarter of treated patients with acromegaly, especially when using ultrasensitive GH assays or in patients receiving SSAs, a fact that the clinician should take into consideration when making clinical decisions.
OBJECTIVE:Growth hormone (GH) and insulin-like growth factor I (IGF-I) are the principal biomarkers used to assess disease activity in acromegaly, and any discrepancy between them renders interpretation of results inconclusive. Purpose of this study was to assess the frequency of this discrepancy and identify parameters that might affect its occurrence. DESIGN: A systematic review of MEDLINE and Scopus was performed (1987-2013) followed by a meta-analysis to address the frequency of discrepant results between GH and IGF-I levels. Meta-regression and subgroup analyses were performed assessing the effects of the year of publication, the different types of GH testing and GH assays used, as well as the impact of treatment with somatostatin analogues (SSAs) on the occurrence of this discrepancy. RESULTS: The analysis retrieved 39 eligible studies totalling 7071 patients. The pooled discordance rate between GH and IGF-I was 25·7% (95% CI: 22·3-29·4), and the predominant format was that of elevated IGF-I with normal GH levels (15·3%, 95% CI: 12·5-18·7). No significant correlation between the discordance rate and the year of publication was shown; whereas, the use of ultrasensitive GH assays resulted in higher discordance rates (30·7%, 95% CI: 25·9-35·9 vs 19·8%, 95% CI: 14·1-27·2, P = 0·04) as did treatment with SSAs (32·5%, 95% CI: 27·8-37·4) vs (21·6%, 95% CI: 17·8-25·6, P = 0·001). CONCLUSIONS: Discrepancy between GH and IGF-I results is encountered in a quarter of treated patients with acromegaly, especially when using ultrasensitive GH assays or in patients receiving SSAs, a fact that the clinician should take into consideration when making clinical decisions.
Authors: Alireza Ghajar; Pamela S Jones; Francisco J Guarda; Alex Faje; Nicholas A Tritos; Karen K Miller; Brooke Swearingen; Lisa B Nachtigall Journal: J Clin Endocrinol Metab Date: 2020-03-01 Impact factor: 5.958
Authors: Robert D'Arcy; C Hamish Courtney; Una Graham; Steven Hunter; David R McCance; Karen Mullan Journal: Endocrinol Diabetes Metab Date: 2017-12-27
Authors: Renato Cozzi; Maria R Ambrosio; Roberto Attanasio; Alessandro Bozzao; Laura De Marinis; Ernesto De Menis; Edoardo Guastamacchia; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Pietro Maffei; Maurizio Poggi; Vincenzo Toscano; Michele Zini; Philippe Chanson; Laurence Katznelson Journal: Endocr Metab Immune Disord Drug Targets Date: 2020 Impact factor: 2.895
Authors: C Bona; N Prencipe; A M Berton; F Bioletto; M Parasiliti-Caprino; V Gasco; E Ghigo; S Grottoli Journal: J Endocrinol Invest Date: 2022-06-24 Impact factor: 5.467